An Open Label Randomised Phase II Trial of RNActive Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2016
At a glance
- Drugs CV 9104 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors CureVac
- 07 Jun 2017 Biomarkers information updated
- 29 Apr 2016 Status changed from active, no longer recruiting to discontinued.
- 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.